Measuring financial risk protection in health benefits packages: scoping review protocol to inform allocative efficiency studies by Abou Jaoude, GJ et al.
1Abou Jaoude GJ, et al. BMJ Open 2019;9:e026554. doi:10.1136/bmjopen-2018-026554
Open access 
Measuring financial risk protection in 
health benefits packages: scoping 
review protocol to inform allocative 
efficiency studies
Gerard Joseph Abou Jaoude,   Jolene Skordis-Worrall,   
Hassan Haghparast-Bidgoli  
To cite: Abou Jaoude GJ, 
Skordis-Worrall J, Haghparast-
Bidgoli H.  Measuring financial 
risk protection in health benefits 
packages: scoping review 
protocol to inform allocative 
efficiency studies. BMJ Open 
2019;9:e026554. doi:10.1136/
bmjopen-2018-026554
 ► Prepublication history and 
additional material for this 
paper are available online. To 
view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2018- 
026554).
Received 8 September 2018
Revised 19 April 2019
Accepted 24 April 2019
Institute for Global Health, 
University College London, 
London, UK
Correspondence to
Mr Gerard Joseph Abou Jaoude;  
 gerard. jaoude. 15@ ucl. ac. uk
Protocol
© Author(s) (or their 
employer(s)) 2019. Re-use 
permitted under CC BY. 
Published by BMJ.
AbstrACt
Introduction To progress towards Universal Health 
Coverage (UHC), countries will need to define a health 
benefits package of services free at the point of use. 
Financial risk protection is a core component of UHC and 
should therefore be considered a key dimension of health 
benefits packages. Allocative efficiency modelling tools can 
support national analytical capacity to inform an evidence-
based selection of services, but none are currently able 
to estimate financial risk protection. A review of existing 
methods used to measure financial risk protection can 
facilitate their inclusion in modelling tools so that the latter 
can become more relevant to national decision making in 
light of UHC.
Methods and analysis This protocol proposes to 
conduct a scoping review of existing methods used 
to measure financial risk protection and assess their 
potential to inform the selection of services in a health 
benefits package. The proposed review will follow the 
methodological framework developed by Arksey and 
O’Malley and the subsequent recommendations made 
by Levac et al. Several databases will be systematically 
searched including: (1) PubMed; (2) Scopus; (3) Web of 
Science and (4) Google Scholar. Grey literature will also 
be scanned, and the bibliography of all selected studies 
will be hand searched. Following the selection of studies 
according to defined inclusion and exclusion criteria, key 
characteristics will be collected from the studies using 
a data extraction tool. Key characteristics will include 
the type of method used, geographical region of focus 
and application to specific services or packages. The 
extracted data will then be charted, collated, reported 
and summarised using descriptive statistics, a thematic 
analysis and graphical presentations.
Ethics and dissemination The scoping review proposed 
in this protocol does not require ethical approval. The final 
results will be disseminated via publication in a peer-
reviewed journal, conference presentations and shared 
with key stakeholders.
IntroduCtIon
background
The political and academic focus on Universal 
Health Coverage (UHC) continues to grow 
globally, as highlighted by the inclusion of 
UHC as target 3.8 in the UN Sustainable 
Development Goals (SDGs).1 According to 
WHO, ‘UHC means that all individuals and 
communities receive the health services they 
need without suffering financial hardship’.2 
This definition by WHO is not prescriptive 
but is clear in outlining that UHC does not 
involve providing all possible health services 
free of charge for everyone. Instead, UHC 
entails the provision of a defined package of 
effective services that are of sufficient quality 
and maximise health, equity and protection 
from financial hardship.3–5 
Given the resource constraints that coun-
tries face, particularly low and middle-in-
come countries, challenging decisions will 
need to be made on what services will be 
provided free of charge and which services 
will not.6 7 When working towards UHC, 
governments will therefore have to define a 
strengths and limitations of this study
 ► This protocol proposes to conduct the first scoping 
review of methods used to measure financial risk 
protection.
 ► The proposed review aims to outline financial risk 
protection measurement methods and detail their 
application to specific services or packages to as-
sess how they could be included in allocative effi-
ciency modelling.
 ► The review will be carried out by the correspond-
ing author only, under the supervision of coauthors, 
which introduces a greater margin for error and 
potential bias for the screening and data extraction 
stages.
 ► While the strengths, weaknesses and applications of 
different methodologies will be discussed, the quali-
ty of included studies will not be considered.
 ► A consultation stage is proposed in this protocol, 
which can improve the comprehensiveness and rel-
evance of the final review.
 o
n
 1 June 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-026554 on 28 May 2019. Downloaded from 
2 Abou Jaoude GJ, et al. BMJ Open 2019;9:e026554. doi:10.1136/bmjopen-2018-026554
Open access 
health benefits package that is free at the point of use, 
sometimes referred to as a basic or essential package of 
health services. Health financing reforms, and how best 
to implement selected services to maximise quality and 
access, will also need to be considered.6–10 Best practice in 
priority setting commonly involves a transparent, system-
atic and evidence-based approach with high levels of 
stakeholder involvement.6 11 Due to financial and human 
resource constraints, countries seeking to embark on 
these complex health system reforms will require admin-
istrative and analytic support for evidence-based decision 
making.6 12 13
Modelling tools can help support national analytical 
capacity and facilitate evidence-based priority setting.6 14 15 
Allocative efficiency analyses may be especially useful in 
this context as they are able to estimate and compare 
the health impact of various packages of services, with 
different budgets, while considering trade-offs between 
desired objectives—for example, minimising disease inci-
dence or mortality.16 17
To date, allocative efficiency analyses have commonly 
been used to inform decision making for national disease 
control programmes, such as national tuberculosis or HIV 
programmes.15 18 19 There is largely unexplored potential 
for allocative efficiency analyses to inform priority setting 
across diseases, while considering the costs, effectiveness, 
equity impact and financial risk protection of health 
benefits packages. The literature on how to consider 
costs and effectiveness is well established, but there is less 
research on the inclusion of equity measures,20–22 and 
to our knowledge, financial risk protection has not yet 
been incorporated into allocative efficiency modelling 
analyses.
rationale
Links between poverty and health have been studied 
extensively, highlighting the importance of socio-eco-
nomic status and income inequality as determinants 
of health.23–25 Likewise, indebtedness due to medical 
expenses is one of the main pathways into and a major 
cause of remaining trapped in poverty.26–28 For individ-
uals or households, particularly those with low income, 
medical expenses due to health shocks can put at risk 
or negatively impact non-medical consumption causing 
financial strain or hardship.29 30 Financial risk protec-
tion can therefore be understood as protection against 
the latter by the partial or full subsidisation of healthcare 
costs through mechanisms such as public financing and 
formal, informal or self-provided insurance.31 Several 
measures of financial risk protection currently exist, 
but the most frequently used indicators, adopted both 
by WHO and the World Bank, are measures of financial 
hardship and can be categorised into catastrophic health 
expenditure and impoverishment. Catastrophic health 
expenditure occurs when the proportion of a household’s 
medical expenses relative to its income or capacity to pay 
exceeds a defined threshold.32–34 Measures of impoverish-
ment on the other hand, aim to capture the number of 
households pushed into, or deeper into, poverty due to 
healthcare costs.34 35
It is estimated that 808 million people incurred cata-
strophic health expenditures in 2010.36 Financial risk 
protection to avert catastrophic health expenditure and 
medical impoverishment is a core component of UHC. 
It is explicitly referred to in target 3.8 of the SDGs, but 
countries are not on track to meet targets for financial 
risk protection.37 When defining or updating national 
health benefits packages, governments should therefore 
consider financial risk protection as a key dimension of 
the priority setting process alongside the maximisation 
of health benefits. If allocative efficiency and model-
ling analyses are to inform policies for UHC and the 
contents of health benefits packages, a method to esti-
mate financial risk protection must be incorporated into 
the analyses. A scoping review of financial risk protection 
measurement methods and how they could be applied 
to allocative efficiency analyses can provide a foundation 
for modelling efforts to become more relevant in light of 
the ongoing push towards UHC. No such review has yet 
been conducted, and this protocol proposes to address 
this gap.
objectives
The primary objective of the proposed scoping review is to 
outline the different methods used to measure financial 
risk protection and discuss their strengths and weaknesses 
as well as application to specific services or health pack-
ages. Subsequently, the review will seek to consider how 
existing financial risk protection measurement methods 
could be applied to allocative efficiency analyses of:
1. Disease-specific health packages.
2. Health benefits packages that address multiple 
diseases.
The secondary objective of the review will be to build 
on the work carried out by the World Bank and WHO 
to track progress towards UHC and financial risk protec-
tion.38–41 The review will compare the amount of research 
on financial risk protection by country and region 
against the burden of financial hardship to establish any 
mismatch between research focus and burden.
MEthods And AnAlysIs
Scoping reviews benefit from a breadth of content 
by providing an overview of all the research in a given 
subject area. They also achieve depth through the 
mapping and interpretation of research.42 The objec-
tives of the proposed review lend themselves well to such 
an approach. They are broad in their scope but precise 
in their aim to map existing research on financial risk 
protection measurement methods while considering how 
they could be applied to allocative efficiency analyses. The 
proposed scoping review will follow the six stages outlined 
in the framework by Arksey and O’Malley,42 hereinafter 
referred to as Arksey and O’Malley’s framework, which 
are discussed in detail below. The recommendations 
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by Levac et al,43 who further clarify and build on Arksey 
and O’Malley’s framework, will also be incorporated 
throughout the review process. The reporting of the 
review will comply with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses checklist recently 
developed for scoping reviews.44
stage 1: Identifying the research questions
The overarching question of the proposed review will guide 
the search strategy and the interpretation and reporting of 
the results: what are the different methods currently used 
to measure financial risk protection? This question should 
be broad enough to ensure that all the existing literature is 
captured and analysed in the review. Two subquestions have 
also been identified, which will focus on the application of 
existing methods to health services or packages and their 
potential to be included in allocative efficiency analyses. 
The two subquestions are as follows: (1) how have different 
methods been used to estimate financial risk protection 
for health services or packages? and (2) how could existing 
financial risk protection measurement methods be applied 
to allocative efficiency analyses? These questions will be 
subjected to iterative thinking as the review is carried out. 
While the overarching question is unlikely to change, the 
subquestions proposed may be refined or additional ques-
tions included.
stage 2: Identifying relevant studies
Stage 2 of the scoping review will involve identifying rele-
vant studies for selection. A systematic search strategy, 
which is guided by the overarching question and its 
subcomponents, will be used to carry out this stage of 
the review. The following electronic databases will be 
searched: (1) PubMed; (2) Scopus; (3) Web of Science 
and (4) Google Scholar. The initial set of search terms 
and strategy proposed in table 1 and online supplemen-
tary file 1 respectively, generates 1594 results on PubMed. 
The search terms and search strategy have been formu-
lated to identify research on the measurement of finan-
cial risk protection and how the different methods have 
been applied. Search results will be downloaded and 
imported using EndNote, and duplicates will be deleted 
prior to screening according to the inclusion and exclu-
sion criteria set in stage 3.
Relevant grey literature on financial risk protection and 
UHC published by institutions or organisations working 
on these topics will also be scanned. Examples of such 
institutions or organisations are the WHO, World Bank, 
Disease Control Priorities Network, Centre for Global 
Development, International Decision Support Initiative, 
Health Policy Plus, UN Department of Economic and 
Social Affairs and the Health Intervention and Tech-
nology Assessment Program. The reference lists of all 
literature deemed relevant according to the inclusion 
and exclusion criteria from stage 3 will then be hand-
searched. In line with Arksey and O’Malley’s framework 
and Levac et al, the search terms and search strategy will 
be improved in an iterative process as we become more 
familiar with the literature.
Table 1 List of search terms and search strategy
Search terms for financial risk protection Search terms for methods used and their application
“Financial risk protection” OR
“Financial hardship " OR
“Financial protection” OR
“Financial protection in health” OR
“Catastrophic health expenditure” OR
“Catastrophic medical expenditure” OR
“Catastrophic health expenditure risk” OR
“Catastrophic medical expenditure risk” OR
“Catastrophic health payment” OR
“Catastrophic medical payment” OR
“CHE” OR
“CMP” OR
“Medical induced poverty” OR
“Health induced poverty” OR
“Payment-induced poverty” OR
“Catastrophic payment” OR
“Catastrophic cost” OR
“Health Impoverishment” OR
“Medical Impoverishment” OR
“Extended cost-effectiveness analysis” OR
“ECEA”
“Universal health coverage” OR
“UHC” OR
“Health benefits package” OR
“HBP” OR
“Basic package of health services” OR
“BPHS” OR
“Essential package of health services” OR
“EPHS” OR
“Priority setting” OR
“Health policy” OR
“Resource allocation” OR
“Allocative efficiency” OR
“Methodology” OR
“Measurement” OR
“Modelling” OR
“Distributional analysis” OR
“Tracking” OR
“Monitoring” OR
“Estimating” OR
“Quantifying” OR
“Threshold” OR
“Healthcare financing” OR
“Health insurance” OR
“Social health insurance” OR
“National health insurance”
“National health programs”
 o
n
 1 June 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-026554 on 28 May 2019. Downloaded from 
4 Abou Jaoude GJ, et al. BMJ Open 2019;9:e026554. doi:10.1136/bmjopen-2018-026554
Open access 
stage 3: selecting studies
The third stage of the review will involve setting inclu-
sion and exclusion criteria. Preliminary inclusion and 
exclusion criteria are proposed below, but these will be 
subjected to iterative thinking as specified by Arksey 
and O’Malley. Studies generated by the search will then 
be screened according to the inclusion and exclusion 
criteria in a two-step selection process. The first screen 
will be based on the relevance of the titles and abstracts, 
followed by a second screen after reading the remaining 
articles in full.
Inclusion criteria
Peer-reviewed journal articles and grey literature 
measuring or discussing methodologies for measuring 
financial risk protection will be included. Research esti-
mating or conceptualising financial risk protection using 
either quantitative or qualitative techniques, regardless 
of the year published, geographic location, disease area 
of focus, health services or population groups considered 
will also be included.
Exclusion criteria
Papers that lack discussion either on the methodology 
behind the measures, their application to health services 
or implications for priority setting will be excluded. 
Papers that cannot be accessed through institutional 
log-in or in languages other than English and French will 
also be excluded.
stage 4: Charting the data
The data from studies identified and selected for final 
inclusion in stage 3 will be collected and charted. A data 
collection tool will be developed to collect key characteris-
tics from the journal papers and grey literature included, 
such as the methods used, application to health services 
or packages and country or region of interest. The tool 
will be developed in an iterative manner during the 
data collection process. Any decisions to amend the tool 
during the data collection process and any changes to the 
overall review protocol will be documented and reported 
appropriately. Both descriptive statistics and qualitative 
analyses will then be carried out on the data collected 
before reporting the results.
Data will be aggregated and charted according to 
the different characteristics collected. For example, 
the number of studies conducted by or concerned 
with a given type of method or by geographic region 
of interest. While there is an ongoing initiative to track 
progress towards UHC and financial risk protection 
on a global scale,38–41 this does not map the amount of 
research conducted by geographic region. Therefore, 
using the data extracted, we will attempt to compare 
the amount of research conducted on financial risk 
protection with the burden of financial hardship by 
geographic region. Given that the focus of the proposed 
review is on mapping the different methodologies avail-
able to measure financial risk protection, a thematic 
analysis will also be undertaken to summarise and better 
understand the different approaches and any overlap 
or links between them. The strengths, weaknesses and 
the applications of different methodologies will then be 
discussed and investigated in the review based on the 
data extracted.
stage 5: Collating, summarising and reporting the results
The data collected in stage 4 will be collated, summarised 
and reported to effectively map the different methods 
currently used to measure financial risk protection. 
Papers on the different methods used to measure finan-
cial risk protection will be classified according to the 
different characteristics identified and gathered through 
data extraction and charting. Tables and graphical 
presentations such as bar charts will be used to present 
the data in an aggregated manner to provide an over-
view of the methods and how they could be included in 
allocative efficiency modelling. The latter will be assessed 
according to certain characteristics collected for different 
measurement methods, such as data requirements and 
application to individual health services or packages.
stage 6: Consultation
The consultation stage aims to involve specialists in finan-
cial risk protection and allocative efficiency modelling, 
as these will likely be the primary target audience of the 
work.
The consultation stage was described as optional but 
desirable by Arksey and O’Malley. Since then, the recom-
mendations outlined by Levac et al have suggested this 
should be a required step as it adds methodological rigour. 
In line with the recommendation to establish a clear 
purpose for the consultation, the following two objec-
tives are proposed due to their potential to strengthen 
the review. First, to ascertain whether any methods or 
approaches to measure financial risk protection have 
not been captured by the review. Second, to assess the 
accuracy and instructiveness of the review and the results 
reported.
study timeline
The first and second stages of this study started in June 
2018 and were required to develop this protocol. Stage 
3 of the review commenced in October 2018 and took 
5 months to complete by February 2019. The hand-
searching of included articles and the fourth stage are 
expected to take 4 months and finish by June 2019. An 
additional 2 months have been assigned for stages 5 and 6 
and for reporting the results. The estimated completion 
date of this scoping review is therefore August 2019.
Patient and public involvement
Patients and the public were not involved in the develop-
ment of this protocol. If specialists agree to be involved in 
the consultation stage, details of this will be included in 
the final scoping review.
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EthICs And dIssEMInAtIon
On completion of all the steps outlined in this protocol, 
the findings of the proposed scoping review will be 
disseminated through the submission of a paper for 
peer-reviewed publication and conference presenta-
tions. The findings will also be shared with WHO, the 
Disease Control Priorities Network and other organisa-
tions working to implement and estimate the impact of 
health benefits packages in a move towards UHC or that 
are involved in allocative efficiency modelling. This study 
does not require ethical approval as only secondary data 
will be used.
The proposed scoping review will be the first to 
comprehensively map the status quo of research on 
the measurement of financial risk protection, both in 
terms of methodological developments and empirical 
work. The extraction of data from included literature is 
another advantage given that data extraction does not 
always feature in scoping reviews.45 However, there are 
key limitations to the proposed review. First, the different 
stages have and will continue to be undertaken by the 
corresponding author only, under the supervision of 
coauthors. This introduces a greater margin for error 
and potential bias, particularly for stages 3 and 4.46 47 
Second, while the strengths, weaknesses and applications 
of different methodologies will be discussed, the quality 
of included studies will not be considered as would 
commonly be the case in systematic reviews.45 Third, the 
review will fail to capture some relevant empirical work 
published in languages other than English or French.
The global movement towards UHC is accelerating, and 
as governments undertake policy reforms it is essential 
that the decisions made are transparent, systematic and 
evidence-based. Allocative efficiency analyses can inform 
such reforms through a systematic and evidence-based 
approach. However, measures of financial risk protection 
will need to be incorporated into allocative efficiency 
modelling if the efforts are to be useful and relevant to 
decision makers. The proposed scoping review outlined 
in this protocol can enable the latter by mapping the 
different available approaches for measuring financial 
risk protection and discussing their suitability for analyses 
seeking to inform priority setting in health.
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